Show simple item record

dc.contributor.authorZhong, J.
dc.contributor.authorWang, S.
dc.contributor.authorShen, W.-B.
dc.date.accessioned2019-05-17T12:53:05Z
dc.date.available2019-05-17T12:53:05Z
dc.date.issued2018
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85044600265&doi=10.1038%2fpr.2017.259&partnerID=40&md5=f8815dfaa3b831833687ada571fa0d36
dc.identifier.urihttp://hdl.handle.net/10713/9102
dc.description.abstractPregestational maternal diabetes induces congenital heart defects (CHDs). Cardiac dysfunction after palliative surgical procedures contributes to the high mortality of CHD patients. Autologous or allogeneic stem cell therapies are effective for improving cardiac function in animal models and clinical trials. c-kit + cardiac progenitor cells (CPCs), the most recognized CPCs, have the following basic properties of stem cells: self-renewal, multicellular clone formation, and differentiation into multiple cardiac lineages. However, there is ongoing debate regarding whether c-kit + CPCs can give rise to sufficient cardiomyocytes. A new hypothesis to address the beneficial effect of c-kit + CPCs is that these cells stimulate endogenous cardiac cells through a paracrine function in producing a robust secretome and exosomes. The values of other cardiac CPCs, including Sca1 + CPCs and cardiosphere-derived cells, are beginning to be revealed. These cells may be better choices than c-kit + CPCs for generating cardiomyocytes. Adult mesenchymal stem cells are considered immune-incompetent and effective for improving cardiac function. Autologous CPC therapy may be limited by the observation that maternal diabetes adversely affects the biological function of embryonic stem cells and CPCs. Future studies should focus on determining the mechanistic action of these cells, identifying new CPC markers, selecting highly effective CPCs, and engineering cell-free products. Copyright 2018 International Pediatric Research Foundation, Inc.en_US
dc.description.urihttps://dx.doi.org/10.1038/pr.2017.259en_US
dc.language.isoen_USen_US
dc.publisherNature Publishing Groupen_US
dc.relation.ispartofPediatric Research
dc.subject.meshPregnancy in Diabeticsen_US
dc.subject.meshHeart Defects, Congenitalen_US
dc.subject.meshStem Cellsen_US
dc.titleThe current status and future of cardiac stem/progenitor cell therapy for congenital heart defects from diabetic pregnancyen_US
dc.typeReviewen_US
dc.identifier.doi10.1038/pr.2017.259
dc.identifier.pmid29016556


This item appears in the following Collection(s)

Show simple item record